GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (XSAT:ENZY) » Definitions » Cyclically Adjusted Revenue per Share

Enzymatica AB (XSAT:ENZY) Cyclically Adjusted Revenue per Share : kr0.00 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Enzymatica AB Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enzymatica AB's adjusted revenue per share for the three months ended in Mar. 2024 was kr0.377. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Enzymatica AB's average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enzymatica AB was 7.60% per year. The lowest was 7.60% per year. And the median was 7.60% per year.

As of today (2024-06-10), Enzymatica AB's current stock price is kr9.00. Enzymatica AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.00. Enzymatica AB's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzymatica AB was 39.08. The lowest was 3.19. And the median was 7.81.


Enzymatica AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Enzymatica AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Cyclically Adjusted Revenue per Share Chart

Enzymatica AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enzymatica AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enzymatica AB's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Cyclically Adjusted PS Ratio falls into.



Enzymatica AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enzymatica AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.377/132.2054*132.2054
=0.377

Current CPI (Mar. 2024) = 132.2054.

Enzymatica AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.055 100.432 0.072
201409 0.264 100.161 0.348
201412 0.348 100.225 0.459
201503 0.279 99.950 0.369
201506 0.124 99.995 0.164
201509 0.273 100.228 0.360
201512 0.443 100.276 0.584
201603 0.337 100.751 0.442
201606 0.196 101.019 0.257
201609 0.477 101.138 0.624
201612 0.452 102.022 0.586
201703 0.385 102.022 0.499
201706 0.237 102.752 0.305
201709 0.994 103.279 1.272
201712 0.766 103.793 0.976
201803 0.605 103.962 0.769
201806 0.212 104.875 0.267
201809 0.530 105.679 0.663
201812 0.759 105.912 0.947
201903 0.532 105.886 0.664
201906 0.255 106.742 0.316
201909 0.781 107.214 0.963
201912 0.887 107.766 1.088
202003 1.073 106.563 1.331
202006 0.558 107.498 0.686
202009 1.132 107.635 1.390
202012 1.693 108.296 2.067
202103 0.680 108.360 0.830
202106 0.245 108.928 0.297
202109 0.618 110.338 0.740
202112 0.751 112.486 0.883
202203 0.167 114.825 0.192
202206 0.386 118.384 0.431
202209 0.742 122.296 0.802
202212 0.666 126.365 0.697
202303 0.522 127.042 0.543
202306 0.351 129.407 0.359
202309 0.532 130.224 0.540
202312 0.634 131.912 0.635
202403 0.377 132.205 0.377

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Enzymatica AB  (XSAT:ENZY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzymatica AB was 39.08. The lowest was 3.19. And the median was 7.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enzymatica AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB (XSAT:ENZY) Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB (XSAT:ENZY) Headlines

From GuruFocus

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016